Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA study shows how satellite 'light pollution' hinders space telescopes - 2Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- 3Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- 4Wizz CEO: We’re going to invest $1 b. in Israeli market
- 5Air travelers face higher ticket prices as Iran war drives up oil prices
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Figure out How to Stay away from Normal Handshaking Missteps
- Vote In favor of Your Favored Language Interpretation Administration
- France honors the victims of the Paris attacks' night of terror 10 years on
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
- Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
